We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Metabolon Introduces mVision™
Product News

Metabolon Introduces mVision™

Metabolon Introduces mVision™
Product News

Metabolon Introduces mVision™


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Metabolon Introduces mVision™"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Metabolon, Inc. has announced the launch of mVision, an integrated service providing the biomarker discovery, biochemical pathway analysis, and biological effect intelligence needed by scientists to advance their research programs.

Based on Metabolon's analytic and informatics platforms, mVision is designed to identify biochemical biomarkers from numerous chemical classes and various sample matrices including: plasma, serum, urine, cerebrospinal fluid (CSF), cell extracts, and tissues.

mVision's non-targeted approach to biomarker discovery allows scientists to observe drug- or disease- induced biochemical changes over virtually the entire spectrum of biochemical pathways. This global screening can be accomplished without hypotheses of the biologic or biochemical effects of disease or the investigational drug.

"Together with Metabolon's other solutions, mSelect™, mVivo™, and mProveClinical™, mVision provides scientists with the unified biomarker discovery and pathway analysis platform they need to understand disease processes and to evaluate drug effects throughout their in vitro, in vivo, and human clinical studies," said Dr. John Ryals, president and CEO of Metabolon.

"Because biochemical biomarkers are highly conserved between species, findings from early discovery research can be translated to predict results of later studies, including human clinical trials," Dr. Ryals continued.

"With mVision, Metabolon continues to lead the evolution of metabolomics by extending biochemical signal detection to biomarker identification," said Ryals. "With Metabolon's family of discovery solutions, researchers can more effectively discover biomarkers for disease detection, prognosis, and therapeutic monitoring as well as biomarkers associated with drug toxicity and efficacy."

Advertisement